肝胆相照论坛

标题: 监测治疗的慢性乙型肝炎患者HBV cccDNA的快速周转,通过监 [打印本页]

作者: newchinabok    时间: 2020-5-15 16:57     标题: 监测治疗的慢性乙型肝炎患者HBV cccDNA的快速周转,通过监

本帖最后由 newchinabok 于 2020-5-15 17:13 编辑

https://www.ncbi.nlm.nih.gov/pubmed/32189364
作者: newchinabok    时间: 2020-5-15 17:15

Rapid Turnover of HBV cccDNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients.
Huang Q1, Zhou B2,3, Cai D1, Zong Y1, Wu Y2, Liu S2, Mercier A1, Guo H3,4, Hou J2, Colonno R1, Sun J2.
Author information
Abstract
Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) plays a pivotal role in the establishment and persistence of HBV infection. Understanding the turnover time of preexisting cccDNA pools would be helpful in designing new strategies to clear HBV by fully blocking the de novo generation of cccDNA. In this study, we retrospectively monitored the emergence and reversion of the rtM204I/V mutant, a signature lamivudine resistance (LAMR ) mutation serving as a biomarker of cccDNA turnover in liver biopsies and longitudinal serum samples from two clinical trials. Methodologies were optimized to differentially isolate and sequence HBV virion DNA, cccDNA, and HBV RNA from clinical samples. A strong correlation was observed between LAMR composition of cccDNA with that of serum and intrahepatic HBV RNA in paired liver and serum samples (r=0.96 and 0.90 respectively), suggesting that serum HBV RNA can serve as a surrogate marker of cccDNA genetic composition when liver biopsies are unavailable. LAMR mutations emerged and increased from undetectable to 40%~90% within 16-28 weeks in serum HBV RNA from telbivudine-treated patients experiencing virologic breakthrough. Similarly, in lamivudine-resistant patients who switched to interferon therapy, serum HBV RNA population bearing 100% LAMR mutations fully reversed back to wild type within 24~48 weeks. Conclusion: The genetic composition dynamics of serum HBV RNA and biopsy cccDNA in treated HBV patients indicates that cccDNA turnover occurs relatively rapidly (several months), offering a possibility of HBV cure with finite therapy through completely blocking cccDNA replenishment.
This article is protected by copyright. All rights reserved.
KEYWORDS:
Genetic marker; HBV RNA; Nuc resistance; cccDNA half-life
作者: 乙肝人1949    时间: 2020-5-15 20:20

假装很认真的看懂了
作者: newchinabok    时间: 2020-5-15 20:56

乙肝人1949 发表于 2020-5-15 20:20
假装很认真的看懂了

百度翻译,有道翻译,看懂so  easy
作者: newchinabok    时间: 2020-5-15 21:01

本帖最后由 newchinabok 于 2020-5-15 21:38 编辑

另外两个试验,验证了cccdna更新周期。




欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) Powered by Discuz! X1.5